Search

Search Results
Results 1021 - 1030 of 1131 for Diabetes Type II
  • Dilart HCT
    Drug - 15 Dec 2025
    Consumer Medicine Information (CMI) about Dilart HCT intended for persons living in Australia.
  • Zedace
    Drug - 11 Dec 2025
    Consumer Medicine Information (CMI) about Zedace intended for persons living in Australia.
  • Oral GLP-1 Pills for Weight Loss: How Orforglipron Works
    Health - 17 Nov 2025
    Orforglipron is an emerging oral small-molecule GLP-1 receptor agonist that offers glucose-lowering and weight-loss without injections. Clinical trials show meaningful reductions in A1c and body...
  • Telmisartan/ Amlodipine Viatris
    Drug - 17 Nov 2025
    Consumer Medicine Information (CMI) about Telmisartan/ Amlodipine Viatris intended for persons living in Australia.
  • Iptam
    Drug - 5 Nov 2025
    Consumer Medicine Information (CMI) about Iptam intended for persons living in Australia.
  • Adesan
    Drug - 4 Nov 2025
    Consumer Medicine Information (CMI) about Adesan intended for persons living in Australia.
  • Symtuza
    Drug - 2 Nov 2025
    Consumer Medicine Information (CMI) about Symtuza intended for persons living in Australia.
  • Mizart HCT (New)
    Drug - 23 Oct 2025
    Consumer Medicine Information (CMI) about Mizart HCT (New) intended for persons living in Australia.
  • How FTIR supports quality control of GLP-1 weight loss drugs
    White Paper - 15 Oct 2025
    Discover how FTIR spectroscopy enhances quality control in GLP-1 weight loss drug production by ensuring molecular consistency.
  • Skyclarys
    Drug - 13 Oct 2025
    Consumer Medicine Information (CMI) about Skyclarys intended for persons living in Australia.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback